#USA #LabConnect #Johnson City, Tennessee #Advisory Board #Scott Evangelista

Formation of a Strategic Advisory Board at LabConnect

LabConnect, a renowned provider of central laboratory services and functional service provider solutions, has officially announced the establishment of its strategic advisory board. This formation aims to significantly enhance LabConnect's position as a leader in the global laboratory services market while supporting its ambitious international expansion and substantial investments in technology and innovation.

Purpose and Importance of the Advisory Board

The newly created strategic advisory board is a key initiative designed to help LabConnect achieve its primary objective: to deliver more efficient, transparent, and sustainable solutions for its clients and partners. By bringing together a group of distinguished experts from various fields, LabConnect is well-positioned to enhance its service offerings and market responsiveness.

Among the initial appointees to this board are three prominent figures in the industries of pharmaceuticals and laboratory services:

Scott Evangelista

Mr. Evangelista boasts over 30 years of experience in the pharmaceutical sector. He is currently the CEO of Cairn Therapeutics, Inc., where he oversees the company's strategic direction, fundraising efforts, and stakeholder management. His past roles include serving as executive chairman of Cairn and leading various important projects at Ironshore Pharmaceuticals and IQVIA. His vast experience in strategic management will be invaluable for LabConnect's growth and innovative endeavors.

David Johnston, Ph.D.

Dr. Johnston brings to the board a robust background in scientific leadership and operational management. As the Executive Vice President and Head of Clinical Research at Thermo Fisher, he managed global clinical development and laboratory services post-acquisition of PPD. His extensive knowledge of clinical development operations will aid LabConnect in boosting productivity and optimizing clinical development costs.

Patrick Hastings

Mr. Hastings is an accomplished executive with a proven track record in operations and business development in both the pharmaceutical and clinical laboratory industries. Formerly, he served as Global Vice President at Labcorp, where he led the central laboratory services division. His expertise in laboratory operations, manufacturing, and supply chain management will be critical in driving LabConnect's operational excellence and commercial performance.

Insights from Leadership

Wes Wheeler, CEO of LabConnect, expressed excitement about the new advisory board members, emphasizing the importance of their combined expertise and leadership in guiding LabConnect as it continues to innovate and expand globally. He stated, "We are thrilled to welcome Scott, David, and Patrick to our strategic advisory committee. Their collective insights will be crucial in helping us maintain and elevate our commitment to providing exceptional value to our clients and partners."

Commitment to Healthier Communities

LabConnect is dedicated to fostering healthier communities by assisting its clients in successfully developing new medications for patients across the globe. The establishment of the strategic advisory board marks a significant milestone on LabConnect's journey toward reinforcing its status as a leader in the sector.

About LabConnect

LabConnect offers comprehensive central laboratory services, functional service provider solutions, and scientific consulting services. It also provides data integration and transformation services for complex analytical and logistical studies such as immuno-oncology and rare diseases. The combination of cutting-edge technology, world-class laboratories, and unparalleled expertise enables pharmaceutical companies to rely on LabConnect as a single provider for all their central laboratory service needs.

For more information, visit LabConnect's website or follow them on LinkedIn.